Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000624381 | SCV000741636 | uncertain significance | Inborn genetic diseases | 2016-08-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000812080 | SCV000952382 | uncertain significance | Nemaline myopathy 2 | 2019-05-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with glutamic acid at codon 610 of the NEB protein (p.Gly610Glu). The glycine residue is moderately conserved and there is a moderate physicochemical difference between glycine and glutamic acid. This variant is present in population databases (rs139125293, ExAC 0.05%). This variant has not been reported in the literature in individuals with NEB-related disease. ClinVar contains an entry for this variant (Variation ID: 521170). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |